Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on the stock and has a $8.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Caufield has given his Buy rating due to a combination of factors including promising clinical trial results and strategic partnerships. The company has shown encouraging progress with its inherited retinal disease (IRD) gene therapy, OPGx-LCA5, which demonstrated sustained visual improvements in adult patients over a 12-month period. These results, presented at the ARVO 2025 meeting, suggest potential for meaningful visual restoration, particularly in pediatric patients, which could significantly impact quality of life.
Additionally, Opus Genetics has secured non-dilutive funding through partnerships for the development of other gene therapies targeting retinal diseases, such as OPGx-RDH12 and OPGx-MERTK. The continued development across the IRD platform, along with the progress of partnered phentolamine, supports the Buy rating. The anticipation of further positive data, particularly from pediatric trials expected in the third quarter of 2025, reinforces confidence in the company’s growth potential and therapeutic impact.
Caufield covers the Healthcare sector, focusing on stocks such as Opus Genetics, Diamedica Therapeutics, and Immunic. According to TipRanks, Caufield has an average return of 0.0% and a 45.26% success rate on recommended stocks.